

## Special Issue

# Vaccines Against Enteric Bacterial Pathogens in Poultry

### Message from the Guest Editors

As the poultry industry transitions into the "no antibiotic era," it becomes critically imperative to advance the development of vaccines able to target emerging bacterial diseases that pose a significant economic threat to the poultry industry, with necrotic enteritis caused by *C. perfringens* being a notable example. Additionally, there is a need to control foodborne bacterial pathogens that pose threats to public health, such as *Salmonella* spp., *Campylobacter* spp., *E. coli*, and *L. monocytogenes*. This Special Issue is dedicated to showcasing recent scientific and technical advancements in vaccines that are designed to combat enteric bacterial pathogens in poultry. We extend an invitation for contributions in the form of original research or review articles, focusing on innovative vaccination strategies. This includes exploring the use of recombinant technology and nanotechnology in vaccine development and delivery, as well as investigating new immunomodulators and adjuvants like Toll-like receptor ligands, cytokines, nanoparticles, probiotics, and other novel agents to enhance vaccine immunogenicity and protective efficacy against the aforementioned bacterial pathogens.

### Guest Editors

Dr. Khaled Abdelaziz

Department of Animal and Veterinary Sciences, Clemson University,  
Clemson, SC 29634, USA

Dr. Ahmed Ali

Poultry Diseases Department, Faculty of Veterinary Medicine, Beni-Suef  
University, Beni-Suef 62511, Egypt

### Deadline for manuscript submissions

closed (31 July 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/196267](https://mdpi.com/si/196267)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).